The immunomodulatory tellurium compound ammonium trichloro (dioxoethylene-O,O') tellurate reduces anxiety-like behavior and corticosterone levels of submissive mice. 2017

Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
aDepartment of Molecular Biology, Ariel University, Ariel bThe Safdié AIDS and Immunology Research Center, C.A.I.R. Institute, The Mina and Everard Goodman Faculty of Life Sciences cInterdisciplinary Department, Faculty of Social Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Ammonium trichloro (dioxoethylene-O,O') tellurate (AS101) is a synthetic organotellurium compound with potent immunomodulatory and neuroprotective properties shown to inhibit the function of integrin αvβ3, a presynaptic cell-surface-adhesion receptor. As partial deletion of αvβ3 downregulated reuptake of serotonin by the serotonin transporter, we hypothesized that AS101 may influence pathways regulating anxiety. AS101 was tested in the modulation of anxiety-like behavior using the selectively bred Submissive (Sub) mouse strain that develop anxiety-like behavior in response to an i.p. injection. Mice were treated daily with AS101 (i.p., 125 or 200 μg/kg) or vehicle for 3 weeks, after which their anxiety-like behavior was measured in the elevated plus maze. Animals were then culled for the measurement of serum corticosterone levels by ELISA and hippocampal expression of brain-derived neurotrophic factor (BDNF) by RT-PCR. Chronic administration of AS101 significantly reduced anxiety-like behavior of Sub mice in the elevated plus maze, according to both time spent and entries to open arms, relative to vehicle-treated controls. AS101 also markedly reduced serum corticosterone levels of the treated mice and increased their hippocampal BDNF expression. Anxiolytic-like effects of AS101 may be attributed to the modulation of the regulatory influence integrin of αvβ3 upon the serotonin transporter, suggesting a multifaceted mechanism by which AS101 buffers the hypothalamic-pituitary-adrenal axis response to injection stress, enabling recovery of hippocampal BDNF expression and anxiety-like behavior in Sub mice. Further studies should advance the potential of AS101 in the context of anxiety-related disorders.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005030 Ethylenes Derivatives of ethylene, a simple organic gas of biological origin with many industrial and biological use.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D013691 Tellurium An element that is a member of the chalcogen family. It has the atomic symbol Te, atomic number 52, and atomic weight 127.60. It has been used as a coloring agent and in the manufacture of electrical equipment. Exposure may cause nausea, vomiting, and CNS depression.
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D056747 Immunomodulation Alteration of the immune system or of an immune response by agents that activate or suppress its function. This can include IMMUNIZATION or administration of immunomodulatory drugs. Immunomodulation can also encompass non-therapeutic alteration of the immune system effected by endogenous or exogenous substances. Immunomodulatory Therapy,Immunomodulations,Immunomodulatory Therapies,Therapies, Immunomodulatory,Therapy, Immunomodulatory

Related Publications

Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
February 2014, International journal of molecular sciences,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
June 2007, The FEBS journal,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
March 2004, Cancer research,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
August 2007, Journal of neurochemistry,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
December 1993, Cancer research,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
August 1994, Current eye research,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
October 1998, Journal of immunology (Baltimore, Md. : 1950),
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
October 2016, Neuroscience letters,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
July 2015, International journal of molecular medicine,
Moshe Gross, and Emanuel Stanciu, and Dvora Kenigsbuch-Sredni, and Benjamin Sredni, and Albert Pinhasov
February 2010, Physiology & behavior,
Copied contents to your clipboard!